ADMA Biologics Inc (NASDAQ:ADMA)
| 3.96 BATS BZX Real-Time Price As of 11:33am ET |  -0.05 / -1.25%Today’s Change | 1.85 Today|||52-Week Range 4.30 | +2.06% Year-to-Date |
Latest ADMA News | Press Releases
| Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study Jun 01 / Zacks.com - Paid Partner Content | Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval May 30 / Zacks.com - Paid Partner Content |
| Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design Jun 01 / Zacks.com - Paid Partner Content | Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? May 29 / Zacks.com - Paid Partner Content |
| PepGen (PEPG) Down on Clinical Hold for DM1 Candidate May 31 / Zacks.com - Paid Partner Content | Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails May 26 / Zacks.com - Paid Partner Content |
| J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH May 31 / Zacks.com - Paid Partner Content | Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use May 26 / Zacks.com - Paid Partner Content |
| Pyxis (PYXS) Up on Advancing Cancer Therapy Candidates May 31 / Zacks.com - Paid Partner Content | PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study May 26 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 4.01 |
| Today’s open | 4.04 |
| Day’s range | 3.96 - 4.04 |
| Volume | 8,344 |
| Average volume (3 months) | 2,346,672 |
| Market cap | $906.9M |
Data as of 11:33am ET, 06/02/2023
Growth & Valuation
| Earnings growth (last year) | +35.11% |
| Earnings growth (this year) | +72.73% |
| Earnings growth (next 5 years) | +14.00% |
| Revenue growth (last year) | +90.36% |
| P/E ratio | NM |
| Price/Sales | 4.98 |
| Price/Book | 5.96 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| COGTCogent Biosciences I... | +0.09 | +0.71% |
| MORMorphoSys AG | +0.11 | +1.72% |
| TWSTTwist Bioscience Cor... | +0.19 | +1.19% |
| MRSNMersana Therapeutics... | +0.02 | +0.26% |
Data as of 11:34am ET, 06/02/2023
Financials
| Next reporting date | August 9, 2023 |
| EPS forecast (this quarter) | -$0.03 |
| Annual revenue (last year) | $154.1M |
| Annual profit (last year) | -$65.9M |
| Net profit margin | -42.77% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Ramsey, New Jersey |
Forecasts
